Cooley LLP announced today that it advised Depomed, Inc. in its sale of interests in royalty and milestone payments in the Type 2 diabetes therapeutic area to PDL BioPharma, Inc. for $240.5 million. Depomed is a specialty pharmaceutical company that commercializes products for pain and neurology related disorders.
The Cooley team advising Depomed on the sale was led by partners Mischi a Marca and Glen Sato and included partner and head of the firm’s medical device practice Mark Weeks; partner Bill Morrow (tax); partners Francis Fryscak and Howard Morse (antitrust); special counsel Marina Remennik; and associates Jason Savich and Rena Kaminsky.
Related Posts:
- Cooley Advises ProteinSimple in $300 Million Sale to Techne Corporation
- Cooley Represents IDEV Technologies in Its Acquisition by Abbott Labs
- Cooley Advises Jazz Pharmaceuticals in Acquisition of ADX-N05
- Cooley Advises Hot Topic in its $600 Million Sale to Sycamore Partners
- Cooley Advises Method Products in Sale to Ecover